Background
==========

Recent examples of successful cancer therapeutics such as Gleevec, Herceptin, and Iressa suggest that the concept of 'molecular targeted therapy' is applicable to human cancers of diverse tissue and genetic origin.[@b1-cin-1-2011-149] 'Oncogene addiction' is a term to describe a phenomenon in which the growth and survival of tumors are impaired by the inactivation of a single oncogene.[@b2-cin-1-2011-149] There are several established relationships between genetic alterations and corresponding targeted therapies, and efforts to identify further genetic alterations are underway. Mechanisms of genetic alterations include mutations (*EGFR* in lung cancer), translocations (*BCR-ABL* in chronic myeloid leukemia), and gene amplifications (*ERBB2* in breast cancer).[@b1-cin-1-2011-149]

Interestingly, some oncogenes are altered in only a subset of cancer patients. For examples, *ERBB2* is amplified and over-expressed in about 25%--30% of breast cancer patients, whereas *EGFR* is mutated in about 20% of lung cancer patients. Cancer Outlier Profile Analysis (COPA) is a computational method that identifies gene expression profiles that are pathogenically over-expressed in only a subset of patients.[@b3-cin-1-2011-149],[@b4-cin-1-2011-149] *AGTR1* is an example of potential target genes identified by applying the COPA method to the Oncomine database.[@b5-cin-1-2011-149]

A database with a large sample size is a great advantage when searching for genes over-expressed in only a subset of patients. For example, identifying genes over-expressed in 50 out of 1000 patients is easier and more reliable than identifying genes over-expressed in 2 out of 40 patients. Although the sample size of most individual gene expression studies rarely exceeds one thousand, a data set of nearly ten thousand samples (ie, GeneSapiens database) can be created by a combined analysis of multiple data sets.[@b6-cin-1-2011-149] Recent work has shown that analysis of a large microarray data set compiled from many data sets can reveal novel findings that are difficult to observe in the individual studies.[@b7-cin-1-2011-149] For a combined analysis, data sets created by the Affymetrix platforms (ie, U133A and U133plus2) offer several advantages. First, most gene expression data sets have been created using the Affymetrix platforms. Second, many data sets are accompanied by raw CEL files so that users can preprocess them as they wish. We have collected human tissue gene expression data sets produced using the Affymetrix U133A and U133Plus2 platforms from public resources, and built a large-scale gene expression database of more than 40,000 samples.

Construction and Content
========================

More than 24300 (U133plus2; 306 data sets) and 16400 (U133A, 241 data sets) samples were collected from public resources, including Gene Expression Omnibus,[@b8-cin-1-2011-149] Array Express,[@b9-cin-1-2011-149] and Expression Project for Oncology.[@b10-cin-1-2011-149] Whenever CEL files were available (288/306 for U133plus2 and 192/241 for U133A), we pre-processed them using the MAS5 algorithm using the affy package.[@b11-cin-1-2011-149] We chose the MAS5 algorithm because it is a single-array algorithm in which expression values are independent of other data. We then normalized each sample to a target density of 500. For data sets without CEL files but pre-processed by the MAS5 algorithm (18/306 for U133plus2 and 49/241 for U133A), we used expression measures downloaded from the web source and normalized them to a target density of 500. We identified samples described in more than one dataset, and cleaned them up from duplications. We then classified each sample according to tissue and disease types ([Table 1](#t1-cin-1-2011-149){ref-type="table"}) based on information given in each dataset. Most samples (∼75%) were classified into either cancer or normal, but about 20% of samples were classified into other diseases including neurodegenerative diseases, immune-related diseases, and organ-specific diseases. In each tissue type, we also classified each sample into more detailed clinical subtypes such as estrogen receptor positive breast cancers or high grade serous carcinoma of the ovary etc, as described in the original data source. We also collected expression data for more than 3000 samples comprising nearly 1000 different cancer cell lines across tissues, and processed them using the same method ([Table 2](#t2-cin-1-2011-149){ref-type="table"}). Broad/Sanger Cell Line Project[@b12-cin-1-2011-149] and GSK's cell line project[@b13-cin-1-2011-149] provided the most abundant expression data sets. For genes with multiple Affymetrix ids, we calculated the average of the multiple probes. The system implementation is based on an Apache web server, JavaScript and PHP scripts for data processing, Open flash charts and R scripts for image production, and MySQL as a backend database.

Utility and Discussion
======================

GENT can be searched using either a gene symbol or an Affymetrix id. DB search results are presented in one of three ways: 1) cancer-normal samples across tissues 2) cancer cell lines across tissues, and 3) detailed phenotypes in a tissue of choice. Raw data for the searched gene are available for download, so users can analyze them as they wish. Users can search multiple gene symbols or Affymetrix ids for cancer-normal samples across tissues.

As an example, we show a pattern of *ERBB2* expression in diverse cancer and normal tissues ([Fig. 1](#f1-cin-1-2011-149){ref-type="fig"}) and in diverse cancer cell lines ([Fig. 2](#f2-cin-1-2011-149){ref-type="fig"}). As expected, the over-expression of *ERBB2* in a subset of breast cancer patients is obvious. Besides, over-expression of *ERBB2* in a subset of lung, ovarian, and stomach cancer patients is observed as well. Indeed, Herceptin is being tested in the treatment of lung, ovarian, and stomach cancer; Last year, an international multi-center study showed the effectiveness of Herceptin in patients with *ERBB*2-positive stomach cancer patients.[@b14-cin-1-2011-149]

The pattern of *ERBB2* expression in diverse cell lines provides interesting information as well. First, similar patterns are observed between cancer cell lines and tissues ([Figs. 1](#f1-cin-1-2011-149){ref-type="fig"} and [2](#f2-cin-1-2011-149){ref-type="fig"}). The *ERBB2* is not only over-expressed in a subset of breast, lung, ovary, and gastric tumor tissues, but it is also over-expressed in a subset of cell lines from those four tissues ([Fig. 2](#f2-cin-1-2011-149){ref-type="fig"}). Second, information on its expression in specific cell lines is provided as raw data for convenience during in vitro experiments. Here, HCC1954 or B-BT-474 (breast), SKOV3 (ovary), and NCI-N87 or MKN7 (stomach) are good cell lines for observing the effects of siRNA knock-down of the *ERBB2*, a first step to show if it is a critical oncogene ([Fig. 2](#f2-cin-1-2011-149){ref-type="fig"}). The information provided by the cell line database allows users to skip laborious RT-PCR steps necessary for selecting cell lines for in vitro experiments.

As a second example, we show a pattern of *MET* expression in diverse normal and tumor tissues. MET is a tyrosine kinase receptor for hepatocyte growth factor and its mutations and amplifications are associated with papillary renal carcinoma.[@b1-cin-1-2011-149] Again, the over-expression of MET in a subset of renal cancers is clearly shown ([Supplementary Fig. 1](#s1-cin-1-2011-149){ref-type="supplementary-material"}). Besides, MET is over-expressed in a subset of liver, melanoma, and gastric cancer patients, suggesting that MET can be a target for a subset of liver, melanoma and gastric cancer patients.

Finally, users can search detailed phenotypes in a specific tissue of interest. For example, if a user selects a brain tissue for detailed information, patterns of expression in diverse brain diseases including Alzheimer's disease, Parkinson's disease, and subtypes of brain tumors are presented. We provide an example of ovarian data set (GSE12172) in [Figure 3](#f3-cin-1-2011-149){ref-type="fig"}. Here, ovarian cancer is further classified into subtypes based on tumor stages. We parsed detailed clinical information given in each data set and provide them in a user-friendly manner.

One may be concerned that the GENT database may present false findings due to noise in the public data because laboratory effects are known to be present in publicly available data sets.[@b11-cin-1-2011-149] We assessed the impact of these effects following Lukk et al's analyses. [@b7-cin-1-2011-149] We selected biological groups (with ten replicates or more) which contain at least two different laboratories. For U133A data sets, we selected 5,089 samples of 92 biological groups produced in 93 laboratories. For each of the biological groups, we computed the average correlation coefficient between the assays from different laboratories within the same group. We also calculated the average correlation coefficient between assays from the same laboratory but belonging to different biological groups. The comparison of the two similarity distributions showed that the biological effects were stronger than the laboratory effects[@b7-cin-1-2011-149] ([Fig. 4](#f4-cin-1-2011-149){ref-type="fig"}). We got similar results with the U133Plus2 data sets, too.

Also, we provide three means to help to identify and minimize false positive findings. First, raw data are provided for the searched gene with data sources (gene expression series id) so that users can check laboratory effects themselves. Second, a data set filtering option is provided so that users can include or exclude particular data sets. Finally, in our opinion, providing results separately in two platforms (U133A and U133plus2) is one way to discern between true and noisy data as congruent results between the two platforms are a sign of good data quality ([Figs. 1](#f1-cin-1-2011-149){ref-type="fig"} and [2](#f2-cin-1-2011-149){ref-type="fig"}).

The COPA method was originally developed to identify genomic aberrations (ie, chromosomal translocations such as TMPRSS2-ETV1) by searching for pairs of samples with mutually exclusive outliers.[@b4-cin-1-2011-149] Currently, the Oncomine database implements the COPA method and provides information on possible outliers. Basically, samples in a dataset are grouped by sample properties, centered by a median value and rescaled by median absolute deviation, and COPA score is calculated at multiple percentiles (ie, 1%, 5%, and 10%). Although we adopted COPA concept in the GENT database, we didn't implement it as suggested in the original paper.[@b3-cin-1-2011-149],[@b4-cin-1-2011-149] Instead, we tried to increase the sample size by collating similar samples across different datasets, so outliers could be detected more reliably. We plan to add the COPA score for each gene in the future. Also, we plan to add additional genomic data such as copy number alterations and genome-wide DNA methylation data to the GENT database so that additional information can be obtained by the integrated analysis of multiple genomic data. We also plan to add gene expression data generated using other platforms (ie, Illumina or Agilent) as more data accumulate. Finally, we plan to add more functions to provide more extensive clinical information which is currently provided in a limited way.

Conclusions
===========

Oncomine[@b5-cin-1-2011-149] and Gene Expression Atlas[@b15-cin-1-2011-149] are two examples of excellent web databases for gene expression information with many useful functions. The two databases provide extensive clinical information given in each collected dataset and many useful search options. To mention a major difference between the two databases, Oncomine focuses on human cancer datasets while Gene Expression Atlas comprises more than 20 organisms including human, mouse, rat, and so on. As those two databases provide rich information, we focused on providing new features for users instead of implementing features already available in those two databases. In our opinion, two aspects of GENT are unique. The first one is the large sample size made possible by the collation of hundreds of datasets into two large datasets, and the second one is the cancer cell line gene expression database which is a convenient tool to select cell lines of interest. The large sample size (\>24300 for U133plus2 and \>16400 for U133A) of GENT provides an enormous advantage in identifying cancer outliers. A cancer cell line gene expression database is a useful resource for target validation by in vitro experiment. We hope GENT will be a useful resource for cancer researchers in many stages from target discovery to target validation.

Supplementary Data
==================

###### 

Pattern of *MET* expression across diverse normal and tumor tissues.
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GENT

:   Gene Expression database of Normal and Tumor tissues;

COPA

:   Cancer Outlier Profile Analysis.

![Pattern of *ERBB2* expression across diverse normal and tumor tissues, **A**) U133plus2 data set, **B**) U133A data set.](cin-1-2011-149f1){#f1-cin-1-2011-149}

![Pattern of *ERBB2* expression across diverse cancer cell lines in U133plus2 data. **A**) Data is shown as multiple boxplots. **B**) Data is shown as a flash chart so users can identify a cell line name by pointing a mouse on each dot.](cin-1-2011-149f2){#f2-cin-1-2011-149}

![Pattern of *LAMB3* expression among ovarian cancer subtypes. **A**) A screenshot of sub-type specific search option. **B**) Pattern of *LAMB3* expression in different stages of ovarian cancer patients from GSE12172 data set.](cin-1-2011-149f3){#f3-cin-1-2011-149}

![Analysis of laboratory effects by comparing distribution of correlation coefficients among three different groups: Distribution of all pairwise correlations between the samples in the dataset (black), distribution of average similarities between the sample subgroups from different laboratories within the same biological group (green), distribution of average similarities between the sample subgroups from different biological groups within the same laboratory (red).](cin-1-2011-149f4){#f4-cin-1-2011-149}

###### 

The number of tissue samples according to tissue types (U133plus2 and U133A).

  **Tissue**        **U133plus2**   **U133A**   **Total**          
  ----------------- --------------- ----------- ----------- ------ -------
  Abdomen           13              0           0           0      13
  Adipose           1               59          0           12     72
  Adrenal gland     14              5           0           0      19
  Bladder           39              14          87          15     155
  Blood             4693            639         3130        1099   8974
  Brain             785             568         592         1627   3572
  Breast            1954            251         2635        91     4931
  Cervix            74              12          64          34     184
  Colon             1294            206         256         27     1783
  Endometrium       72              61          0           9      142
  Esophagus         48              9           24          28     109
  GIST              64              0           0           0      64
  Head and neck     202             14          21          2      239
  Heart             0               0           0           41     41
  Kidney            573             105         366         66     1110
  Liver             182             25          156         52     415
  Lung              441             225         582         364    1612
  Muscle            0               177         0           331    508
  Myometrium        0               0           0           24     24
  Ovary             859             21          341         9      1230
  Pancreas          132             55          13          8      208
  Prostate          308             45          244         83     680
  Sarcoma           493             0           0           0      493
  Skin              290             28          499         59     876
  Small intestine   13              6           0           22     41
  Stomach           268             57          46          18     389
  Testis            4               6           184         13     207
  Thyroid           62              25          44          25     156
  Tongue            0               11          0           4      15
  Uterus            155             12          0           24     191
  Vagina            3               5           0           0      8
  Vulva             21              14          0           0      35
  Total             13057           2655        9284        4087   29083

###### 

The number of cancer cell lines according to tissue types (U133plus2 and U133A).

  **Tissue**            **U133plus2**   **U133A**   **Total**
  --------------------- --------------- ----------- -----------
  Adrenal gland         0               2           2
  Biliary tract         0               6           6
  Bladder               30              40          70
  Blood                 229             142         371
  Bone                  12              32          44
  Brain                 149             117         266
  Breast                239             199         438
  Cervix                23              23          46
  Colon                 143             56          199
  Connective tissue     9               0           9
  Endometrium           0               11          11
  Esophagus             12              25          37
  EWT                   7               0           7
  Eye                   5               2           7
  Kidney                29              40          69
  Leukemia              0               4           4
  Liver                 33              16          49
  Lung                  358             325         683
  Lymphoma              73              1           74
  Muscle                10              0           10
  Myeloma               7               24          31
  Ovary                 24              43          67
  Pancreas              50              18          68
  Pharynx               6               0           6
  Placenta              9               2           11
  Prostate              12              18          30
  Rectum                7               0           7
  Sarcoma               8               0           8
  Skin                  129             73          202
  Soft tissue           0               19          19
  Stomach               56              24          80
  Testis                0               4           4
  Thyroid               12              13          25
  Upper aerodigestive   0               24          24
  Urinary tract         0               20          20
  Vulva                 9               3           12
  Total                 1714            1336        3050
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